Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference
- PMID: 39792303
- PMCID: PMC11982078
- DOI: 10.1007/s40264-024-01510-9
Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference
Conflict of interest statement
Declarations. Funding: The cost of attending the conference was covered by The International Federation of Pharmaceutical Manufacturers and Associations. This cost included the use of the conference center, including meals, and accommodation (not for industry participants). Travel costs were not covered. Conflicts of Interest: Vincent Bauchau has been an employee of GSK and received travel support for the conference and owns restricted shares in the GSK group of companies as part of his past employee remuneration. Phil Bryan, Kourtney Davis, Antonella Fretta, Sarah Frise, Sonja Gandhi-Banga, Corinne Jouquelet-Royer, Alena Khromava, Lin Li, Sarah MacDonald, Lydie Marcelon, Robert Massouh, Wilhelmine Meeraus, Karen Naim, Heather Rubino, Sarah Sellers, Laurence Serradell, Laurence Torcel-Pagnon, and Jamie Wilkins are employees of pharmaceutical companies as included in their respective affiliations and each own restricted shares and received travel support for the conference. Kaatje Bollaerts, Jim Buttery, Robert Chen, Daniel R. Feiken, Hector S. Izurieta, Raj Long, and Dale Nordenberg have no competing interests to declare that are relevant to this article. Flor M. Munoz has been a data safety monitoring board member for Pfizer and Meissa, a clinical investigator for studies from Pfizer and Gilead, and an advisory board member for Sanofi, Merck, AstraZeneca, GSK, and Moderna. Hanna Nohnek has contributed to Innovatives Medicine Initiative-funded projects, is the chair of the World Health Organization Strategic Advisory Group of Experts on Immunization and a member of the Finish Institute for Health and Welfare National Immunization Technical Advisory Group. Daniel Salmon has received grant support through the stated affiliation from Merck and the Vaccine Confidence Fund and has served as a paid advisory board member for Merck and Moderna. Disclosure: These contributions represent the authors’ own best judgement. They do not bind or obligate any institution. The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions or policies of the World Health Organization. Ethics Approval: Not Applicable. Consent for Publication: All authors consented for publication. Consent for Participation: Not Applicable. Availability of Data and Material: Not applicable. Code Availability: Not Applicable. Author Contributions: All authors contributed to the conceptualization, concept, and design of the manuscript. Content generation and preparation of the first draft was performed by Sonia Banga, Kaatje Bollaerts, Kourtney Davis, Robert Chen, Antonella Fretta, Sarah Frise, Corinne Jouquelet-Royer, Alena Khromava, Sarah MacDonald, Lydie Marcelon, Robert Massouh, Wilhelmine Meeraus, Karen Naim, Dale Nordenberg, Heather Rubino, Sarah Sellers, Laurence Torcel-Pagnon, and Jamie Wilkins. All authors commented on subsequent versions and approved the final manuscript.
Similar articles
-
Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe.Vaccine. 2019 May 31;37(25):3278-3289. doi: 10.1016/j.vaccine.2019.04.073. Epub 2019 May 6. Vaccine. 2019. PMID: 31072735 Review.
-
Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.Drug Saf. 2023 Apr;46(4):327-333. doi: 10.1007/s40264-023-01290-8. Epub 2023 Apr 11. Drug Saf. 2023. PMID: 37040044 Free PMC article.
-
Marketing the COVID-19 vaccine and the implications for public health.Vaccine. 2021 Aug 9;39(34):4766-4768. doi: 10.1016/j.vaccine.2021.07.015. Epub 2021 Jul 13. Vaccine. 2021. PMID: 34281742 Free PMC article.
-
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.Vaccine. 2020 Dec 22;38 Suppl 2:B1-B7. doi: 10.1016/j.vaccine.2019.07.081. Epub 2019 Oct 31. Vaccine. 2020. PMID: 31677952
-
Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data.Hum Vaccin Immunother. 2024 Dec 31;20(1):2315659. doi: 10.1080/21645515.2024.2315659. Epub 2024 Feb 26. Hum Vaccin Immunother. 2024. PMID: 38407186 Free PMC article. Review.
Cited by
-
De-risking vaccine development: lessons, challenges, and prospects.NPJ Vaccines. 2025 Jul 30;10(1):177. doi: 10.1038/s41541-025-01211-z. NPJ Vaccines. 2025. PMID: 40739092 Free PMC article. Review.
References
-
- Salmon D, Kathrine Yih W, Lee G, et al. Sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance. Health Aff. 2012;31(11):2518–27. 10.1377/hlthaff.2012.0104. - PubMed
-
- Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013;31(40):4448–58. 10.1016/j.vaccine.2013.06.032. - PubMed
-
- Id.DRIVE [Internet]. 2024 [cited 2024 Nov 11]. Available from: https://iddrive.eu. Accessed 24 June 2024.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous